In vivo blockade of the Fas-Fas ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice

Journal of Autoimmunity

Volumn 16, Issue 4, 2001, Pages 431-440

  Mahiou, Jérôme ^a   Walter, Ulrich ^a   Lepault, Françoise ^a   Godeau, François ^b   Bach, Jean François ^a   Chatenoud, Lucienne ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

Author keywords

Apoptosis; Autoimmunity; Diabetes; FAS CD95; Tolerance

Indexed keywords

CYCLOPHOSPHAMIDE; FAS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0034954901     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2000.0476     Document Type: Article

References (63)

1. Type-I diabetes: A chronic autoimmune disease of human, mouse, and rat
2. Insulin-dependent diabetes mellitus as an autoimmune disease
3. The nonobese diabetic mouse as a model of autoimmune diabetes: Immune dysregulation gets the NOD
4. Apoptosis is the mode of beta-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse
5. Beta cell apoptosis in T cell-mediated autoimmune diabetes
6. The role of Fas in autoimmune diabetes
7. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice
8. Inhibition of autoimmune diabetes by Fas ligand: The paradox is solved
9. Significant role for Fas in the pathogenesis of autoimmune diabetes
10. Mechanisms of beta cell death in diabetes: A minor role for CD95
11. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha
12. Apoptosis of pancreatic beta-cells detected in accelerated diabetes of NOD mice: No role of Fas-Fas ligand interaction in autoimmune diabetes
13. Beta-cell destruction in NOD mice correlates with Fas (CD95) expression on beta-cells and proinflammatory cytokine expression in islets
14. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide
15. Cyclophosphamide-induced diabetes in NOD/WEHI mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus
16. Ontogeny of regulatory and effector T-cells in autoimmune NOD mice
17. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice
18. Programmed cell death in the pathogenesis of murine IDDM: Resistance to apoptosis induced in lymphocytes by cyclophosphamide
19. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses
20. Regulation of delayed-type hypersensitivity reactions by cyclophosphamide-sensitive T cells
21. Reinduction of experimental allergic encephalomyelitis in convalescent Lewis rats with cyclophosphamide
22. Experimental allergic encephalomyelitis in the Lewis rat. A model of predictable relapse by cyclophosphamide
23. Early quantitative and functional deficiency of NK1(+)- like thymocytes in the NOD mouse
24. Lack of L-selectin expression by cells transferring diabetes in NOD mice: Insights into the mechanisms involved in diabetes prevention by Mel-14 antibody treatment
25. Characterization of peripheral regulatory CD4(+) T cells that prevent diabetes onset in nonobese diabetic mice
26. Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate 'active tolerance' in the nonobese diabetic mouse
27. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice
28. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity
29. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
30. Monoclonal antibody-mediated tumor regression by induction of apoptosis
31. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
32. The role of APO-1-mediated apoptosis in the immune system
33. The Fas death factor
34. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice
35. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells
36. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
37. Expression and function of mouse Fas antigen on immature and mature T cells
38. Activated B cells express functional Fas ligand
39. A role for CD95 ligand in preventing graft rejection
40. Fas ligand-induced apoptosis as a mechanism of immune privilege
41. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice
42. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
43. Fas-and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis
44. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis
45. The Fas/Fas ligand system is involved in the pathogenesis of autoimmune myocarditis in rats
46. Cyclophosphamide therapy of severe lupus nephritis
47. Cyclophosphamide therapy in systemic lupus erythematosus
48. Alkylating agents
49. The effect of cyclophosphamide treatment on lymphocyte subsets in the nonobese diabetic mouse: A comparison of various lymphoid organs
50. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells
51. Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells
52. B cells in systemic autoimmune disease: Recent insights from Fas-deficient mice and men
53. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
54. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
55. B7/CD28 Costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes
56. Down-regulation of homing receptors after T cell activation
57. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death
58. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells
59. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice
60. Analysis of the roles of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice
61. Pancreatic islet-specific T-cell clones from nonobese diabetic mice
62. T helper cell subsets in insulin-dependent diabetes
63. In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice